&w=3840&q=100)
Why is Alembic Pharmaceuticals' share in demand today? Key details here
Around 12:15 PM, Alembic Pharmaceuticals shares continued to trade near day's high, up 13.34 per cent at 1,101.45 per share. In comparison, BSE Sensex was trading 0.20 per cent lower at 83,892.01 levels.
What triggered the rally in Alembic Pharmaceuticals share price today?
Alembic Pharmaceuticals' share price surged after the company received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection in two dosage strengths — 20 mg/10 mL and 50 mg/25 mL single-dose vials.
The approved product is a therapeutic equivalent of Doxil Liposome Injection by Baxter Healthcare Corporation, and is used in the treatment of ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma.
As per IQVIA, the drug has an estimated market size of around $29 million for the 12 months ending March 2025.
With this approval, Alembic Pharmaceuticals now holds a total of 224 ANDA approvals from the USFDA, including 201 final and 23 tentative approvals.
Alembic Pharmaceuticals Q4 results
Alembic Pharmaceuticals reported a 12 per cent year-on-year (Y-o-Y) decline in net profit for the fourth quarter of FY25 (Q4FY25), which stood at ₹157 crore, despite a 17 per cent rise in net sales to ₹1,770 crore.
Ebitda grew 9 per cent to ₹286 crore, with the margin at 16 per cent, while profit before tax increased 5 per cent to ₹192 crore. READ MORE
About Alembic Pharmaceuticals
Alembic Pharmaceuticals is among the leading Indian pharmaceutical companies with a legacy dating back to 1907.
Headquartered in Vadodara, Gujarat, the company has built a strong global presence through its vertically integrated operations that span research, development, manufacturing, and marketing of pharmaceutical products.
It is publicly listed and is known for its robust pipeline of generic drugs, backed by advanced R&D infrastructure and regulatory approvals from key markets, including the USFDA.
With manufacturing units located in Gujarat and Sikkim, and R&D centres across Vadodara, Hyderabad, and New Jersey, Alembic Pharmaceuticals serves both domestic and international markets.
Its subsidiaries, Alembic Pharmaceuticals Inc. and Alembic Global Holding SA, further support its global footprint, making it a trusted name in both branded and generic pharmaceuticals worldwide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
8 hours ago
- Business Standard
INR reverses yesterday's losses as US dollar stays feeble
Indian Rupee appreciated today, recovering after recent losses amid a feeble undertone in the US dollar. INR closed at 85.51 per US dollar, up 25 paise on the day. The US dollar index tanked near 96 mark following recent slide that has pulled it down nearly 10% in first half of the year. The US dollar index tested its lowest since February 2022 as rising US fiscal worries pressured the greenback. Local stocks were steady. The BSE Sensex rose or 0.11% to 83,697.29, while added 0.10% to 25,541.80. On the NSE, USD/INR futures closed down 0.27% at 85.63. With today's gains, the Rupee has reversed bulk of the losses seen in last session Powered by Capital Market - Live News
Deccan Herald
11 hours ago
- Deccan Herald
Stock markets close higher on buying in Reliance, HDFC Bank
The 30-share BSE Sensex rose by 90.83 points or 0.11 per cent to settle at 83,697.29 with 13 of its constituents closing higher and 17 in the red. During the day, it rallied 267.83 points or 0.32 per cent to 83,874.29.
New Indian Express
13 hours ago
- New Indian Express
Indian equity markets end with modest gains after a subdued session
CHENNAI: Indian equity markets ended a largely calm Tuesday session with a modest positive tilt. The BSE Sensex hit a high of 83,874.29 intraday before closing at 83,697.29, up 90.83 points (0.11%). The NSE Nifty50 also edged higher, gaining 24.75 points (0.1%) to end at 25,541.80. Trading remained cautious amid Asian market uncertainty and closely watched US–India trade talks ahead of the July 9 tariff deadline. The Nifty Midcap100 closed flat, while the Smallcap100 fell 0.10%. Sectoral performance varied—PSU banks, metals, oil & gas, consumer durables, healthcare, and pharma showed gains, while autos, IT, energy, FMCG, media, and real estate lagged. Market participation was balanced, with 1,491 stocks rising and 1,452 declining on the NSE; 77 stocks were unchanged. Notably, 96 stocks hit 52-week highs and 24 hit lows. Upper circuit triggers were hit by 119 stocks, while 43 stocks hit lower circuit limits. The total market cap of NSE-listed companies stood at Rs. 5.36 trillion. Volatility eased, as the India VIX dropped 2.01% to 12.5. The focus remains on ongoing trade negotiations with the US. Financial Times reports that India may finalise an interim trade deal this week, aiming to avoid the 26% tariff imposed on reciprocal US goods after July 9. That came after earlier roadblocks over agriculture, steel, and auto tariffs. Markets are also tracking US signals—White House says the July 9 tariff deadline isn't fixed and may be extended. Reuters notes that bilateral talks with partners including India are ongoing, with only the UK deal finalised so far. Investor sentiment is cautiously optimistic, expecting a 'mini-deal' or interim agreement. President Trump hinted a "big deal" could open India's markets . However, detailed issues like agriculture and industrial concessions remain unresolved.
